Gene Expression Profiling for Thyroid Cancer Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for cancer diagnosis, particularly for thyroid cancer, are subjective, prone to indeterminate results, and lack rigorous methods for determining diagnostic accuracy, leading to unnecessary surgeries and treatment complications.
Innovation Solution
A method involving the analysis of gene expression products in biological samples, using trained algorithms to classify samples based on differential gene expression levels, and normalizing technical variables to improve diagnostic accuracy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If cytological examination and imaging techniques are used for cancer diagnosis, then the diagnosis can be performed and is inexpensive, but the results are subjective and prone to indeterminate results
Solution Approach 1:
The patent replaces subjective mechanical examination methods with objective molecular profiling techniques. Instead of relying on cytological examination and imaging that produce indeterminate results, the invention uses gene expression analysis and molecular markers to provide definitive diagnostic classification, substituting mechanical/visual assessment with molecular-level detection.
Solution Approach 2:
The patent changes the diagnostic parameters from morphological and imaging-based measurements to molecular expression profiles. By measuring gene expression levels, protein markers, and molecular pathways rather than relying on subjective visual assessment, the system achieves more precise and objective diagnostic results.
2Reliability
If routine diagnostic methods are used, then the diagnosis can be performed, but they lack a rigorous method for determining the probability of an accurate diagnosis
Solution Approach 1:
The patent implements feedback mechanisms through validated molecular profiles and diagnostic algorithms that continuously refine diagnostic accuracy. The system uses reference ranges, control samples, and statistical validation to provide reliable probability assessments of diagnostic accuracy, allowing for quality control and performance monitoring.
Solution Approach 2:
The patent performs preliminary validation and characterization of molecular markers before they are used for diagnosis. Through pre-analytical steps including validation studies, establishment of reference ranges, and verification of marker specificity, the system ensures reliable diagnostic results before actual diagnosis occurs.
3Object-affected harmful factors
If newer generation targeted treatments are used, then side effects are reduced, but the cost is prohibitive and effectiveness is limited to cancers reliant on specific pathways
Solution Approach 1:
The patent performs preliminary molecular profiling and pathway analysis to identify which cancers are reliant on specific metabolic or signaling pathways before treatment is initiated. This pre-characterization enables selective application of targeted therapies only to cancers with matching molecular profiles, maximizing treatment effectiveness while minimizing unnecessary treatments.
Solution Approach 2:
The patent uses molecular profiling feedback to guide treatment selection and adjust therapy based on identified pathway dependencies. By continuously monitoring molecular markers and pathway activity, the system can adapt treatment strategies to match the specific molecular characteristics of each cancer, optimizing both effectiveness and cost-efficiency.
4Loss of time
If cytological analysis and imaging techniques are used, then the diagnosis can be made, but they are incapable of detecting a malignant growth at very early stages
Solution Approach 1:
The patent performs preliminary molecular detection before morphological changes become apparent. By analyzing gene expression patterns, protein markers, and molecular pathways at early stages, the system can detect malignancy before it progresses to stages detectable by conventional imaging or cytology, enabling earlier intervention.
Solution Approach 2:
The patent substitutes mechanical imaging techniques with molecular detection methods that can identify cancer at the cellular and molecular level before structural changes occur. This molecular-level analysis enables detection of early-stage malignancies that would be invisible to conventional imaging modalities.
Data Source
AI summary
The present invention relates to compositions and methods for molecular profiling and diagnostics for genetic disorders and cancer, including but not limited to gene expression product markers associated with cancer or genetic disorders. In particular, the present invention provides algorithms and methods of classifying cancer, for example, thyroid cancer, methods of determining molecular profiles, and methods of analyzing results to provide a diagnosis.